Navigation Links
Aureus Pharma Releases New Unified Knowledge Database
Date:8/18/2008

AurSCOPE(R) Global Pharmacology Space and Drug Target Knowledge Databases

Related to Nuclear Receptors and Proteases

PARIS, August 18 /PRNewswire/ -- Aureus Pharma, a leading provider of knowledge management solutions that accelerate life sciences discovery, announced today the release of three new AurSCOPE(R) Target knowledge databases. The new offerings include knowledge databases for the important drug targets Nuclear Receptor and Protease, as well as the centralized product AurSCOPE(R) Global Pharmacology Space (AurSCOPE(R) GPS). AurSCOPE GPS comprises all of the pharmaceutically important therapeutic targets including G-Protein coupled receptors (GPCR), kinases, ion channels, nuclear receptors and proteases.

Nuclear receptor proteins are integral to critical metabolic processes and implicated in diseases including diabetes, cancer, and heart disease. Likewise, proteases are a major focus for therapeutic intervention being linked to viral diseases including HIV, inflammation and neurogenerative disorders.

AurSCOPE GPS and other AurSCOPE Knowledge databases streamline discovery efforts with thorough assessment of selectivity and off-target effects at the earliest stages of the drug discovery pipeline.

"The release of AurSCOPE Global Pharmacology Space (GPS), Nuclear Receptor and Protease represents an exciting milestone for Aureus Pharma. These powerful new products considerably extend Aureus' knowledge management solution by providing our pharmaceutical customers unique access to the druggable therapeutic target space." said Jason Theodosiou, President and CEO of Aureus Pharma. "Using AurSCOPE Knowledge databases, researchers easily employ knowledge-driven hypotheses to drive better informed decisions during drug discovery."

Aureus experts will demonstrate AurSCOPE GPS, AurSCOPE Nuclear Receptor and AurSCOPE Protease products at the American Chemical Society (ACS) meeting in Philadelphia, PA August 18th -21st.

About Aureus Pharma

Aureus Pharma headquartered in Paris, France is a privately held

knowledge management based solutions provider for the life sciences

industry. Aureus Pharma accelerates new drug discovery by providing

knowledge databases which contain high quality quantitative information

for both chemistry and biology. Researchers gain rapid access to

knowledge for important drug target classes as well as ADME/Tox topics.

The information contained in the Aureus Pharma system is of primary

importance to aid in lead discovery and optimization as well as to

build predictive models. For further information on how Aureus Pharma

helps researchers turn data into discovery visit

http://www.aureus-pharma.com

Media Contact

Mary E. Donlan, Ph.D.

Director of Marketing

Aureus Pharma

Phone:+33-1-40-18-57-59 / +33-6-76-19-51-77

mary.donlan@aureus-pharma.com


'/>"/>
SOURCE Aureus Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aureus Pharma Releases AurPROFILER(R) - a New and Powerful Pharmacology Profiling Solution
2. Aureus Pharma Announces Date of 2008 Annual User Symposium
3. QSB Anti-Virulence Platform Inhibits Biofilm Formation by Staphylococcus Aureus MRSA and Candida sp
4. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
5. New ActivePure Technology Proven To Reduce Exposure to Methicillin Resistant Staphylococcus Aureus (MRSA)
6. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
7. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
8. Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
9. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
10. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
11. Ondine Biopharma Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):